Investigational drug · Phase 3
ITI-1284
Also called: JNJ-99245354
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
8
Any phase or sponsor naming "ITI-1284"
First trial start
2024
Aug 5, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ITI-1284", any sponsor or status.
Conditions studied
As listed on its trial records.
- Generalized Anxiety Disorder
- Agitation Associated With Alzheimer's Dementia
- Psychotic Disorders
- Alzheimer Disease
Approved drugs for the same conditions: Alzheimer's disease · Anxiety disorders · Neurology · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "ITI-1284" as an intervention, largest first.
- A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)Pivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT07807865 · 900 participants (planned) · Start Sep 3, 2026 · Primary completion Feb 18, 2030
Drug: ITI-1284 · For: Generalized Anxiety Disorder
Sites: Los Angeles, California; Miami, Florida; Brooklyn, New York
- Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety DisorderPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT06480383 · 705 participants (planned) · Start Aug 5, 2024 · Primary completion Mar 16, 2027
Drug: ITI-1284 10 mg; ITI-1284 20 mg and 1 more · For: Generalized Anxiety Disorder
Sites: Glendale, California; Imperial, California; Lemon Grove, California · 59 sites in all
- A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD TreatmentPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT07856420 · 705 participants (planned) · Start Sep 29, 2026 · Primary completion Sep 20, 2030
Drug: JNJ-99245354; Placebo · For: Generalized Anxiety Disorder
Sites: Temecula, California; Miami, Florida; Springfield, Massachusetts · 4 sites in all
- Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety DisorderPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT06701903 · 570 participants (planned) · Start Nov 21, 2024 · Primary completion Oct 14, 2027
Drug: ITI-1284 10 mg; ITI-1284 20 mg and 1 more · For: Generalized Anxiety Disorder
Sites: Birmingham, Alabama; Little Rock, Arkansas; Rogers, Arkansas · 51 sites in all
- A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's DiseasePivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT06540833 · 370 participants (planned) · Start Aug 15, 2024 · Primary completion Sep 30, 2028
Drug: ITI-1284; Placebo · For: Psychotic Disorders; Alzheimer Disease
Sites: Anaheim, California; Los Alamitos, California; Newport Beach, California · 71 sites in all
- A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's DementiaPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT06651567 · 320 participants (planned) · Start Oct 22, 2024 · Primary completion Dec 28, 2027
Drug: ITI-1284; Placebo · For: Agitation Associated With Alzheimer's Dementia
Sites: Anaheim, California; Costa Mesa, California; Garden Grove, California · 71 sites in all
Intra-Cellular Therapies, Inc.Industry
NCT06299410 · 58 participants · Start Apr 11, 2024 · Primary completion Aug 18, 2026
Drug: ITI-1284 10 mg; ITI-1284 20 mg · For: Healthy Volunteers
Sites: New Haven, Connecticut
Intra-Cellular Therapies, Inc.Industry
NCT06786286 · 8 participants · Start Jan 28, 2025 · Primary completion Mar 26, 2025
Drug: [14C]-ITI-1284 · For: Healthy Volunteers
Sites: Nottingham, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Generalized Anxiety Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- DT120MM120, lysergide tartratePhase 34 trials
Definium Therapeutics US, Inc. · Generalized Anxiety Disorder, Major Depressive Disorder
- BuagafuranPhase 32 trials
Beijing Union Pharmaceutical Factory Ltd · Generalized Anxiety Disorder
- Buagafuran mimicPhase 32 trials
Beijing Union Pharmaceutical Factory Ltd · Generalized Anxiety Disorder
- Toludesvenlafaxine Hydrochloride Sustained-releasePhase 31 trial
Luye Pharma Group Ltd. · Generalized Anxiety Disorder
- ENX-102ENX-102 -dose, ENX-102 mid-dosePhase 23 trials
Engrail Therapeutics INC · General Anxiety Disorder, Social Anxiety Disorder (SAD), Generalized Anxiety Disorder
- RE104Phase 23 trials
Reunion Neuroscience Inc · Adjustment Disorder, Generalized Anxiety Disorder, Postpartum Depression
- CYB004Phase 21 trial
Cybin IRL Limited · Generalized Anxiety Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.